Echo Therapeutics EBIT

As of the most recent data (September 2016), ECTE shows a EBIT of $-5.8M. That compares with $-18M in the prior-year period — up 68.6% year over year. That is above the sector sector average of $-18M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ECTE's EBIT is now $-5.8M (was $-18M) — a 68.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Echo Therapeutics is outperforming or lagging.

The its sector sector average EBIT is about $-18M. Echo Therapeutics is at $-5.8M, which is higher that average. That is roughly 67.4% above the sector mean. Use the comparison chart on this page to see how ECTE stacks up against individual peers as well.

Tracking ECTE's ebit over time shows whether Echo Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-5.8M That compares with $-18M in the prior-year period — up 68.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Echo Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-5.8M) with ownership activity and broader fundamentals.